SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease

Trial Startdrug-coated balloonPositive

AI Analysis

Summary

Translumina has officially initiated the SPARX Global Randomized Controlled Trial evaluating a drug-coated balloon-first strategy in patients with complex coronary disease.

Clinical Trial Data

Importance:4/10

Sentiment:

0.40

clinical trialdrug-coated ballooncoronary diseaserandomized controlled trialmultinational

Related Companies

$GBCMD $TRAX

Read the original article

Published by PR Newswire Clinical Trials on October 12, 2026 6:02 PM

Read Original